Glaukos Corporation

GKOSleader

Glaukos invented the MIGS (micro-invasive glaucoma surgery) category with iStent, and is expanding into sustained-release drug delivery (iDose TR) and keratoconus treatment (Photrexa).

⇄ Compare

Productos e Ingresos

Participación de Ingresos por Producto

Desglose de Ingresos ($370M)

Datos estáticos (cargando finanzas en tiempo real…)

MIGS & Corneal Health (US) (72%)

International (28%)

Composición de segmentos y clientes principales

Detalles del producto

iStent (MIGS)52%

World's smallest FDA-approved medical device — tiny titanium stent implanted in eye during cataract surgery to lower IOP in glaucoma.

iDose TR (Sustained-release)25%

Travoprost intracameral implant providing 18-month drug delivery for glaucoma — no daily eye drops needed.

Photrexa (Corneal Cross-linking)23%

FDA-approved drug for keratoconus cross-linking — combined with UV light to halt corneal thinning.

Relaciones en la Cadena de Suministro

Competidores

alcon

MIGS device market

Impacto: major

Socios

Abbott Laboratories

Cataract procedure integration

Impacto: significant

Contexto macro y de mercado

헬스케어Noticias del sector

메디케어 수가 압박 vs AI 진단 효율화 — 선별적 접근 필요

미국 헬스케어 지출 (2026E)

$4.8T

AI 진단 정확도 개선

+23% vs 기존

UNH 의료손해율

87.3%

약가 협상 대상 의약품

20종 (IRA)

Próximos catalizadores

◆CMS 메디케어 최종 수가 발표 (2026.Q2)◆UNH/HUM/CVS Q1 실적 (2026.04)◆IRA 약가 협상 2차 품목 공개

Últimas noticias

Cargando noticias...

Análisis IA

Haz clic en "Obtener Análisis IA" para un análisis de cadena de suministro de Glaukos Corporation impulsado por IA.

Información de la Empresa

Sede Central

San Clemente, California, USA

Fundación

1998

Empleados

1,400

Sitio Web

glaukos.com

Estado del sector — 헬스케어

Noticias del sector